Verrica Pharmaceuticals reported negative net product revenue of $1.9 million for Q3 2024, including a provision for product returns of $1.7 million. There were no ex-factory sales in the third quarter of 2024 due to slower demand pull through. The company is implementing restructuring efforts to reduce operating expenses by approximately 50% and is exploring strategies to strengthen its balance sheet. New senior leadership appointments were announced, including Dr. Jayson Rieger as CEO and John Kirby as Interim CFO.